Vertex Pharmaceuticals has solid revenue projections for its CF franchise, and a promising drug pipeline, especially in pain.

The PGIM Jennison Growth Fund returned - $10.0%, matching the Russell 1000 Growth Index, which also returned -10.0% in Q1 ...